Samsung Biologics and Eli Lilly partner to establish a new Lilly Gateway Labs site in Korea to accelerate drug discovery and development.
This collaboration signifies a strategic expansion of Lilly's R&D footprint into South Korea, leveraging Samsung Biologics' established infrastructure and expertise. It positions Samsung Biologics as a key partner in global drug development, potentially leading to increased demand for its services and further solidifying South Korea's role as a biopharmaceutical hub. The establishment of Gateway Labs could streamline early-stage research and development, accelerating the path to clinical trials and market.
Samsung Biologics and Eli Lilly to establish a new Lilly Gateway Labs site in Korea.
Partnership aims to accelerate drug discovery and development.
Strengthens South Korea's position as a biopharmaceutical hub.
This partnership directly impacts South Korea's biopharmaceutical sector by attracting significant investment and expertise from a global pharmaceutical leader like Eli Lilly. It enhances the country's capabilities in drug discovery and development, reinforcing its position as a key player in the global biotech landscape.
Partnership aims to accelerate drug discovery and development.
Strengthens South Korea's position as a biopharmaceutical hub.
Sign in to save notes on signals.
Sign In